Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight

The dynamics of the heart failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world.

LAS VEGAS, Jan. 15, 2024 /PRNewswire/ — DelveInsight’s Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Heart Failure Market Report

• According to DelveInsight’s analysis, the market size for congestive heart failure reached USD 6 billion in 2022 across the 7MM and is expected to grow with a significant CAGR by 2032.
• DelveInsight’s analysis reveals that the overall diagnosed prevalent population of congestive heart failure in the 7MM was reported as ~15 million in 2022. 
• Leading heart failure companies such as Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company, and others are developing novel heart failure drugs that can be available in the heart failure market in the coming years.
• The promising heart failure therapies in the pipeline include PC-61815, Omecamtiv Mecarbil, AZD4831, Rexlemestrocel-L (Revascor), Finerenone (Kerendia), Semaglutide 2.4 mg, Sotagliflozin, Furoscix (furosemide injection), HNO (Nitroxyl) Donor (BMS-986231), Lenrispodun (ITI – 214), Levosimendan, CardiAMPCell Therapy, Tirzepatide, and others.
• Surrounded by a potential pipeline targeting the HFrEF patient population, Omecamtiv mecarbil, which is a myosin-binding peptide, could aid cardiac contractility. It is projected to capture a major market share compared to its competitors.

Discover which therapies are expected to grab the major heart failure market share @ Heart Failure Market Report

Heart Failure Overview

Heart failure, also referred to as congestive heart failure, is categorized into left-side heart failure and right-side heart failure. Cor pulmonale, another term for heart failure, indicates that elevated blood pressure in the pulmonary arteries and the right ventricle causes right-side heart failure. Structural and functional limitations in the myocardium, leading to impaired ventricular filling or blood ejection by the heart, trigger Heart Failure. The primary cause of heart failure is often the diminished utility of the left ventricular myocardium, accompanied by dysfunction in the pericardium, myocardium, endocardium, heart valves, or large vessels, either individually or in combination.

Initially, the signs and symptoms of heart failure are subtle and can be mistaken for common signs of aging. These heart failure symptoms result from the accumulation of extra fluid or congestion, causing vessel blockages. The congestion that initiates in the lungs progresses to affect various parts of the body as the disease advances, eventually leading to a reduction in cardiac output in later stages.

Heart Failure Epidemiology Segmentation

The heart failure epidemiology section provides insights into the historical and current heart failure patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The heart failure market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Heart Failure
• Gender-specific Cases of Heart Failure
• Ejection Fraction-specific 3 Cases of Heart Failure 
• NYHA Class-specific Cases of Heart Failure
• Type-specific Cases of Heart Failure
•  Age-specific Cases of Heart Failure

Heart Failure Treatment Market 

The primary therapeutic strategy for heart failure characterized by reduced ejection fraction (HFrEF) involves inhibiting neurohormonal activity through various classes of agents. It is essential to approach heart failure treatment as an ongoing process. Initially, emphasis is placed on lifestyle modifications, including smoking cessation, alcohol and caffeine avoidance, stress reduction, decreased fluid intake, and limiting dietary salt. Concurrently, optimization of essential medical interventions is pursued. Subsequent treatment stages may entail more intensive medical therapies or the implementation of devices such as pacemakers or implantable cardioverter-defibrillators (ICDs). Additional options encompass cardiac resynchronization therapy (CRT), biventricular pacing, or ventricular assist devices (VADs). In cases where conventional interventions prove ineffective, heart transplantation becomes a viable option, potentially enhancing both survival rates and the quality of life for individuals facing severe heart failure.

Presently, the management of heart failure relies on angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Furthermore, various treatments, including aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, nitrates, and others, are employed for addressing heart failure in affected patients. Recently sanctioned therapies for heart failure include Entresto and Corlanor. ACE inhibitors play a crucial role in heart failure treatment as they are vital medications that aid in lowering blood pressure and promoting blood vessel relaxation. This, in turn, enhances blood flow, enabling the heart to effectively pump blood throughout the body. Examples of ACE inhibitors encompass captopril, enalapril, ramipril, quinapril, lisinopril, among others.

To know more about heart failure treatment guidelines, visit @ Heart Failure Management 

Heart Failure Pipeline Therapies and Key Companies

• PC-61815: Otsuka Pharmaceutical
• Omecamtiv Mecarbil: Cytokinetics
• AZD4831: AstraZeneca
• Rexlemestrocel-L (Revascor): Mesoblast
• Finerenone (Kerendia): Bayer
• Semaglutide 2.4 mg: Novo Nordisk
• Sotagliflozin: Lexicon Pharmaceuticals
• Furoscix (furosemide injection): scPharmaceuticals
• HNO (Nitroxyl) Donor (BMS-986231): Bristol-Myers Squibb
• Lenrispodun (ITI – 214): Intra-Cellular Therapies
• Levosimendan: Tenax Therapeutics
• CardiAMPCell Therapy: BioCardia
• Tirzepatide: Eli Lilly and Company

Learn more about the FDA-approved drugs for heart failure @ Drugs for Heart Failure Treatment 

Heart Failure Market Dynamics

The dynamics of the heart failure market are expected to change in the coming years. Many major companies are investing in various mechanisms of action for the treatment of congestive heart failure, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, cell therapies, and others. These investments are expected to bolster the heart failure market in the future. The heart failure market growth is further fueled by the rising incidences of cardiovascular diseases (CVDs), increasing cases of coronary artery disease, lifestyle changes, a growing number of smokers, and the escalating prevalence of obesity, diabetes, hypertension, among other factors.

Furthermore, many potential therapies are being investigated for the treatment of heart failure, and it is safe to predict that the treatment space will significantly impact the heart failure market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the heart failure market in the 7MM.

However several factors may impede the growth of the heart failure market. Heart failure is a complex syndrome, and while current treatments can help slow heart failure risks and progression in some patients, they are not effective for all. Despite the ability of current therapies to slow disease progression, there exists a significant unmet medical need for patients who continue to deteriorate, even when optimized on the standard of care, as heart failure cannot be cured.

Moreover, heart failure treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the heart failure market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the heart failure market growth.

Scope of the Heart Failure Market Report

• Therapeutic Assessment: Heart Failure current marketed and emerging therapies
• Heart Failure Market Dynamics: Key Market Forecast Assumptions of Emerging Heart Failure Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Heart Failure Market Access and Reimbursement

Discover more about heart failure drugs in development @ Heart Failure Clinical Trials

Table of Contents

Related Reports

Heart Failure Pipeline

Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key heart failure companies, including Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, among others.

Heart Failure Epidemiology Forecast

Heart Failure Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted heart failure epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Heart Failure Market

Acute Heart Failure Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key acute heart failure companies, including Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, among others.

Acute Heart Failure Pipeline

Acute Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute heart failure companies, including Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur  

[email protected]

+91-9650213330

www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

SOURCE DelveInsight Business Research, LLP

Go to Source